Quick Answer
Larimar Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2019.
Larimar Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$165.67M -105.5% |
-$80.60M -118.1% |
-$36.95M -4.5% |
-$35.35M +30.2% |
-$50.64M -19.2% |
-$42.48M -83.7% |
| Diluted EPS | — | -$1.32 -57.1% |
-$0.84 +38.7% |
-$1.37 +53.6% |
-$2.95 +17.4% |
-$3.57 |
| Total Assets | $145.84M -27.2% |
$200.22M +108.7% |
$95.94M -24.1% |
$126.41M +60.7% |
$78.67M -24.9% |
$104.69M +1912.8% |
| Cash and Equivalents | $85.41M +157.1% |
$33.22M +24.2% |
$26.75M -0.3% |
$26.82M -61.7% |
$70.10M +2.9% |
$68.15M +6654.0% |
| Stockholders Equity | $78.08M -54.6% |
$171.81M +110.2% |
$81.72M -26.3% |
$110.90M +72.2% |
$64.41M -28.2% |
$89.69M +13023.9% |
| R&D Expense | $154.22M +110.5% |
$73.28M +164.8% |
$27.67M +14.1% |
$24.25M -36.8% |
$38.40M +22.3% |
$31.41M +51.1% |
| Operating Income | -$172.50M -89.8% |
-$90.89M -117.7% |
-$41.76M -14.3% |
-$36.53M +27.6% |
-$50.47M -17.9% |
-$42.80M -84.4% |
| Shares Outstanding | 83.09M +30.2% |
63.82M +45.3% |
43.91M +1.5% |
43.27M +144.3% |
17.71M +15.2% |
15.37M +152.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2020 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$47.71M | -207.8% | -82.2% |
| Diluted EPS | September 30, 2025 | -$0.61 | -154.2% | -48.8% |
| Total Assets | September 30, 2025 | $187.35M | -14.5% | +24.9% |
| Cash and Equivalents | September 30, 2025 | $90.14M | +157.1% | +337.8% |
| Stockholders Equity | September 30, 2025 | $139.04M | -29.9% | +16.0% |
| R&D Expense | September 30, 2025 | $44.93M | +222.8% | +92.3% |
| Operating Income | September 30, 2025 | -$49.50M | -171.0% | -78.1% |
| Shares Outstanding | September 30, 2025 | 85.59M | +34.1% | +33.7% |
- Larimar Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2019.
- Larimar Therapeutics, Inc. reported Net Income of -$165.67 million for fiscal year 2025.
- Larimar Therapeutics, Inc. showed a decrease of -105.5% in Net Income compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported Diluted EPS of $1.32 per share (loss) for fiscal year 2024.
- Larimar Therapeutics, Inc. showed a decrease of -57.1% in Diluted EPS compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported Total Assets of $145.84 million for fiscal year 2025.
- Larimar Therapeutics, Inc. showed a decrease of -27.2% in Total Assets compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported Cash and Equivalents of $85.41 million for fiscal year 2025.
- Larimar Therapeutics, Inc. showed an increase of +157.1% in Cash and Equivalents compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported Stockholders Equity of $78.08 million for fiscal year 2025.
- Larimar Therapeutics, Inc. showed a decrease of -54.6% in Stockholders Equity compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported R&D Expense of $154.22 million for fiscal year 2025.
- Larimar Therapeutics, Inc. showed an increase of +110.5% in R&D Expense compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported Operating Income of -$172.50 million for fiscal year 2025.
- Larimar Therapeutics, Inc. showed a decrease of -89.8% in Operating Income compared to the prior fiscal year.
- Larimar Therapeutics, Inc. reported Shares Outstanding of 83.09 million shares for fiscal year 2025.
- Larimar Therapeutics, Inc. showed an increase of +30.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: